Crolibulin

Crolibulin is a small molecule neoflavonoid and tubulin polymerization inhibitor that acts as a vascular disrupting agent (VDA) and apoptosis inducer. It binds to the colchicine-binding site on tubulin, leading to microtubule destabilization, cell cycle arrest at the G2/M phase, and induction of apoptosis in cancer cells[3][4][6]. By disrupting tumor vasculature, it impairs blood flow to tumors, resulting in anti-tumor activity. Crolibulin has demonstrated cytotoxicity against various cancer cell lines and has been investigated primarily for the treatment of advanced solid tumors—including anaplastic thyroid carcinoma—and lymphomas[2][4][5][7]. The drug was initially developed by EpiCept Corporation (later acquired by Immune Pharmaceuticals)[5].

Other names

crolibulinCrolibulin [USAN]CROLIBULIN [INN]CROLIBULIN [WHO-DD]crolibulinacrolibulinecrolibulinumCrinobulin